Lanatoside C

Generic Medicine Info
Indications and Dosage
Atrial fibrillation, Atrial flutter, Chronic heart failure
Adult: Initially, 2 mg/day until clinical improvement or for 3-7 days. Maintenance: 250 mcg to 1 mg/day.
Child: Infant: Initially, 200-300 mcg/day. Maintenance: 100-150 mcg/day. 1-5 yr: Initially 300-600 mcg/day. Maintenance 100-200 mcg/day. >5 yr: 600 mcg to 1 mg/day. Maintenance: 250 mcg/day.
Elderly: Reduce dose.
Woff-Parkinson-White syndrome; hypertrophic obstructive cardiomyopathy; ventricular fibrillation.
Special Precautions
CV disease; partial heart block, sinus node disorders, acute myocarditis, chronic constrictive pericarditis, acute MI, severe heart failure, severe pulmonary disease, hypokalaemia, hypomagnesaemia, hypercalcaemia, hypoxia, myxoedema, acute glomerulonephritis. Renal impairment. Elderly. Neonates. Lactation.
Adverse Reactions
Nausea, vomiting, anorexia, diarrhoea, abdominal pain, headache, facial pain, fatigue, weakness, dizziness, drowsiness, disorientation, mental confusion, bad dreams, delirium, acute psychoses, hallucinations, convulsions, blurred vision, disturbance in colour vision, thrombocytopenia, gynaecomastia.
Potentially Fatal: May cause or aggravate heart failure; supraventricular or ventricular arrhythmias; conduction abnormalities.
Drug Interactions
Increased risk of cardiac glycoside toxicity with drugs that produce electrolyte imbalance (e.g. diuretics, amphotericin B, corticosteroids, corticotropin, edetate disodium, laxatives, sodium polystyrene sulfonate, glucagon, large doses of dextrose, dextrose-insulin infusions). Synergistic inotropic and toxic effects with calcium. Additive negative effects on AV conduction with β-blockers, calcium-channel blockers. Increased risk of arrhythmias with sympathomimetics, rauwolfia alkaloids.
Lab Interference
False-positive ST-T segment changes during exercise testing.
Description: Lanatoside exerts positive inotropic effect by increasing the concentration of intracellular calcium, thereby increasing myocardial contraction.
Absorption: About 60% is absorbed (oral); peak plasma concentration after 1 hr.
Distribution: Protein-binding: 25%, to albumin; detected in breast milk.
Excretion: Via urine (23% as digoxin and metabolites after oral admin; as unchanged drug after IV) and via faeces.
MIMS Class
Cardiac Drugs
Disclaimer: This information is independently developed by MIMS based on Lanatoside C from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in